19. Mai 2022 – The European Medicines Agency (EMA) started evaluating the use of a booster dose of Novavax's Covid-19 vaccine, Nuvaxovid, in adults. Nuvaxovid is a vaccine for preventing Covid-19 in people aged 18 years and older. Nuvaxovid contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein), which has been produced in the laboratory.

For more information, see here.